0.03Open0.03Pre Close0 Volume632 Open Interest10.00Strike Price0.00Turnover261.04%IV161.20%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry0.03Extrinsic Value100Contract SizeAmericanOptions Type0.0456Delta0.0505Gamma128.00Leverage Ratio-0.0066Theta0.0001Rho5.83Eff Leverage0.0007Vega
uniQure NV Stock Discussion
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s Disease
uniQure has received the FDA's Regenerative Medicine Advanced Therapy (RMAT) designation for its investigational gene therapy, AMT-130, for Huntington’s disease. This designation is based on 24-month interim data from Phase I/II clinical trials released in December 2023 and represents a significant milestone.
AMT-130 is the firs...
No comment yet